We want to identify first-in-class drugs for genetically complex neurological disorders for which no treatment is available.

We will accomplish this by correlating drug profiles generated with barcoding in disease-specific iPSC models to clinical features.

Our drug discovery engine in patient-derived disease models integrates underlying molecular root causes responsible for neurological disorders.

The technological progress made in biomedical research has radically changed the view to new treatment strategies.

Modern genetic technologies can deliver disease-relevant targets but are insufficient to refill the empty drug discovery pipeline. Innovative and systems level pharmacological strategies are needed to substantially improve both early and late stages of the drug discovery process.

Aging societies are confronted with dramatically increasing costs of the health care systems. The genetic causes of many severe diseases, which do not only affect the elderly, have been identified, but effective treatment options are rarely available.

We are providing cost-effective and highly innovative solutions to address critical and unmet needs of the pharmaceutical industry. We will help to improve the cost-benefit ratio in the process of the development of better medicines.